Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.58 USD

85.58
407,379

-0.07 (-0.08%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $86.18 +0.60 (0.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CVS Health (CVS) to Expand Health Care Access With New Pact

by Zacks Equity Research

CVS Health's (CVS) recent collaboration establishes new Accountable Care that focuses on health equity, coordinated care and enhanced access.

Zacks Equity Research

QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

by Zacks Equity Research

QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.

Zacks Equity Research

Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now

by Zacks Equity Research

Veeva Systems' (VEEV) slew of product launches raises optimism about the stock.

Zacks Equity Research

Abbott's (ABT) New FDA Approval to Improve Patient Outcome

by Zacks Equity Research

Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.

Zacks Equity Research

Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe

by Zacks Equity Research

Walgreens Boots (WBA) continues to progress in transforming the pharmacy business and the method of delivering healthcare through physical stores and digital channels.

Zacks Equity Research

Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials

by Zacks Equity Research

Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.

Zacks Equity Research

Charles River (CRL) to Develop RNA-based Therapy With New Pact

by Zacks Equity Research

Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.

Zacks Equity Research

ShockWave Medical (SWAV) Posts Solid Preliminary Q4 Revenues

by Zacks Equity Research

ShockWave Medical's (SWAV) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its U.S. Coronary business.

Zacks Equity Research

Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays

by Zacks Equity Research

Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.

Zacks Equity Research

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.

Zacks Equity Research

Shockwave Medical's (SWAV) New Buyout to Boost Patient Outcome

by Zacks Equity Research

Shockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool.

Zacks Equity Research

Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe

by Zacks Equity Research

Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.

Zacks Equity Research

Here's Why You Should Retain Neogen (NEOG) Stock for Now

by Zacks Equity Research

Investors are optimistic about the strong performance of Neogen's (NEOG) Animal Safety and Food Safety segments.

Zacks Equity Research

Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI), owing to its strong product portfolio.

Zacks Equity Research

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

Zacks Equity Research

IDEXX (IDXX) Aided by Global Growth, Solid Instrument Placement

by Zacks Equity Research

IDEXX's (IDXX) rapid assay revenue growth is supported by solid volume gains in the United States and benefits from net price increases.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Zacks Equity Research

BD's (BDX) New Robotic Track System to Boost Lab Workflow

by Zacks Equity Research

BD's (BDX) new robotic track system for the BD Kiestra microbiology laboratory solution is expected to streamline lab workflows.

Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Preliminary FY22 Sales Meet Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) preliminary results meet market expectation. While certain product categories are driving growth, macro headwinds continue to hurt the top line.

Zacks Equity Research

Catalent's (CTLT) New Deal to Utilize Its Zydis ODT Technology

by Zacks Equity Research

Catalent's (CTLT) latest development and license agreement is expected to accelerate the administration of therapeutic doses of active drugs.

Zacks Equity Research

Here's Why Investors Should Retain Globus Medical (GMED) Stock

by Zacks Equity Research

Investors are optimistic about Globus Medical's (GMED) robust performance across several international markets.

Zacks Equity Research

Charles River (CRL) to Advance DNA Programs With New Launch

by Zacks Equity Research

Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.

Zacks Equity Research

NuVasive (NUVA) Suffers From Macro Headwinds, Price Issue

by Zacks Equity Research

NuVasive (NUVA) believes that its 2022 guidance is appropriately conservative, considering macroeconomic pressures on net sales and operating profit.

Zacks Equity Research

Intuitive Surgical (ISRG) Reports Mixed Preliminary Q4 Revenues

by Zacks Equity Research

Intuitive Surgical's (ISRG) revenue growth in the fourth quarter is driven by increase in procedure volume, partially offset by resurgence of COVID-19 in China.